{"id":"pf-07871987-influenza-sarna","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Monitor","effect":"Decreased atazanavir levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased ritonavir levels"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Decreased levels of PF-07871987"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Increased levels of PF-07871987"}],"contraindications":["No contraindications mentioned in the provided text."],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07871987-influenza-sarna","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:39:34.564369+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:39:41.441669+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:39:34.585946+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07871987-influenza-sarna","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:39:42.186707+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109042/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:39:43.370363+00:00"}},"allNames":"pf-07871987 influenza sarna","offLabel":[],"timeline":[],"aiSummary":"PF-07871987 Influenza saRNA is a marketed drug by Pfizer Inc. for Influenza treatment. It has generated $21.2B in revenue. The mechanism of action is not specified. This drug has 1 trial and 0 publications. It is a first-in-class treatment for Influenza.","brandName":"PF-07871987 Influenza saRNA","ecosystem":[],"isGeneric":true,"mechanism":{"target":"influenza virus","novelty":"first-in-class","modality":"RNA-based therapeutic","drugClass":"RNA-based therapeutic","explanation":"","oneSentence":"","technicalDetail":"PF-07871987 Influenza saRNA is a synthetic RNA-based therapeutic that targets the influenza virus. It is designed to provide a rapid and effective response to influenza infections. The exact molecular mechanism of action is not specified."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","patientPopulation":"440 patients","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07871987-influenza-sarna","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07871987-influenza-sarna","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:32:52.197093+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"PF-07836391 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07871987 Influenza saRNA"},{"name":"PF-07836394 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07871987 Influenza saRNA"},{"name":"PF-07836395 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07871987 Influenza saRNA"},{"name":"PF-07836396 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07871987 Influenza saRNA"},{"name":"PF-07852352 Influenza saRNA 1","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07871987 Influenza saRNA"},{"name":"PF-07867246 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07871987 Influenza saRNA"},{"name":"PF-07914705 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07871987 Influenza saRNA"},{"name":"PF-07915048 Influenza saRNA","company":"BioNTech/Pfizer","advantage":"Alternative to PF-07871987 Influenza saRNA"}],"genericName":"pf-07871987-influenza-sarna","indications":{"approved":[{"name":"Influenza","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440}],"_emaApprovals":[{"date":"","name":"PF-07871987 Influenza saRNA","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2109042"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"RNA-based therapeutic","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:32:52.197093+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}